Extracellular activation of hydrophilic glucuronide prodrugs by b-glucuronidase (bG) was examined to increase the therapeutic efficacy of bacteria-directed enzyme prodrug therapy (BDEPT). bG was expressed on the surface of Escherichia coli by fusion to either the bacterial autotransporter protein Adhesin (membrane bG (mbG)/AIDA) or the lipoprotein (lpp) outermembrane protein A (mbG/lpp). Both mbG/AIDA and mbG/lpp were expressed on the bacterial surface, but only mbG/AIDA displayed enzymatic activity. The rate of substrate hydrolysis by mbG/AIDA-BL21cells was 2.6-fold greater than by pbG-BL21 cells, which express periplasmic bG. Human colon cancer HCT116 cells that were incubated with mbG/AIDA-BL21 bacteria were sensitive to a glucuronide prodrug (p-hydroxy aniline mustard b-D-glucuronide, HAMG) with an half maximal inhibitory concentration (IC 50 ) value of 226.53 ± 45.4 mM, similar to the IC 50 value of the active drug (p-hydroxy aniline mustard, pHAM; 70.6 ± 6.75 mM), indicating that mbG/AIDA on BL21 bacteria could rapidly and efficiently convert HAMG to an active anticancer agent. These results suggest that surface display of functional bG on bacteria can enhance the hydrolysis of glucuronide prodrugs and may increase the effectiveness of BDEPT.
INTRODUCTION
Tumors are composed of immunosuppressive and hypoxic microenvironments that facilitate the accumulation and replication of bacteria. 1, 2 Numerous studies have thus demonstrated that bacteria can be used as selective anticancer vectors. [2] [3] [4] For example, an attenuated strain of Salmonella typhimurium (VNP20009) that was genetically modified to express cytosine deaminase, a prodrug-converting enzyme, successfully completed Phase I clinical trials. Some tumor colonization was observed at the highest tolerated dose (3 Â 10 8 cfu m À 2 ), with toxicity observed in patients receiving 1 Â 10 9 cfu m À 2 , including thrombocytopenia, diarrhea, anemia, persistent bacteremia, vomiting, nausea, hyperbilirubinemia, hypophosphatemia and elevated alkaline phosphatase. 5, 6 Recently, Salmonella expressing carboxypeptidase G2, 7 Escherichia coli expressing b-glucuronidase (bG) 8 and Salmonella expressing herpes simplex virus thymidine kinase 3 have been shown to generate potent and selective antitumor activity by converting systemically administered prodrugs to active anticancer agents in tumors, while minimizing exposure of normal tissues to active drug. Therefore, bacteria-directed enzyme prodrug therapy (BDEPT) is a promising therapeutic approach for treatment of solid tumors.
Inadequate colonization of bacteria may limit the conversion of prodrugs by BDEPT in some tumors. 9 Thus, methods that increase conversion efficiency of prodrug-activating bacteria within tumors are anticipated to improve the therapeutic efficacy of BDEPT. bG is an attractive prodrug-converting enzyme for selective prodrug therapy, because glucuronide prodrugs can display orders of magnitude with less toxicity than the parent drug, and most antineoplastic agents can be converted to glucuronide prodrugs by employing linkers between the drug and glucuronide moieties. [10] [11] [12] [13] We previously found that extracellular activation of hydrophilic glucuronide prodrugs by cell membrane-anchored bG can increase the antitumor activity and bystander cytotoxic effects of glucuronide anticancer prodrugs. [14] [15] [16] In this study, we fused bG to the amino terminus of the bacterial autotransporter protein adhesin (AIDA-I) or the carboxy terminus of the lipoprotein outermembrane protein A (lpp-ompA) to generate membrane bG (mbG)/AIDA-BL21 and mbG/lpp-BL21 bacteria, respectively. AIDA-I is Gram-negative bacterial autotransporter involved in diffuse adherence, consisting of an N-terminal signal peptide, secreted passenger domain, a linker region and a C-terminal translocator domain, which forms a b-barrel structure in the outer membrane. AIDA-I has been used for the surface expression of a variety of recombinant proteins.
17,18 the lpp-ompA consists of a signal sequence and the first nine amino acids of the E. coli lpp fused with amino acids 46-159 of the E. coli ompA, 19 previously shown to allow display of passenger proteins on E. coli. [20] [21] [22] [23] Expression of bG on the surface of bacteria by lppompA or AIDA-I was hypothesized to increase prodrug conversion efficiency and maximize the therapeutic efficacy of BDEPT ( Figure 1 ).
Surface expression of bG on the BL21 cells was confirmed by enzyme-linked immunosorbent assay. We then examined whether surface-expressed bG can hydrolyze p-nitrophenyl-b-D-glucuronide (PNPG) to p-nitrophenol. In addition, the hydrolytic efficiency of p-nitrophenyl-b-D-glucuronide (PNPG) in mbG/AIDA-BL21, pbG-BL21 (periplasmic bG) and pbG-BL21 lysates were investigated. Finally, the cytotoxic effects of adding mbG/AIDA-BL21 or pbG-BL21 bacteria and HAMG prodrug to HCT116 human colon cancer cells were examined. Our results show that surface expression of bG may provide a strategy to enhance the potency of BDEPT for glucuronide prodrug therapy.
MATERIALS AND METHODS

Bacteria and cell line
E. coli BL21 (F-ompT hsdSB (rB À ,mB À ) gal dcm (DE3); Novagen, San Diego, CA, USA) was used in this study. HCT116 human colorectal adenocarcinoma cells (American Type Culture Collection, Manassas, VA, USA) were cultured in Dulbecco's minimal essential medium (Sigma, St Louis, MO, USA) supplemented with 5% heat-inactivated bovine serum, 100 units per ml penicillin and 100 mg ml À 1 streptomycin (Gibco Laboratories, Grand Island, NY, USA) at 37 1C in 5% CO 2 in humidified air.
Plasmid construction
The coding sequence of bG was amplified by PCR, using the plasmid pRSETB-bG 8 as template and the primers 5 0 -CGGGATCCGGCGGCCGC GTATCCATATGATGTTCCA-3 0 and 5 0 -GGGGTACCTTACTCGAGATCGATCCCG GGTGTCGACTACTTTCGGCG CCTGAGCATC-3 0 , to introduce a hemagglutinin epitope tag and unique restrictions sites as follows: BamHI-NotIhemagglutinin-SfiI-bG-SalI-SmaI-ClaI-KpnI. The PCR fragment was digested with BamHI and KpnI, and cloned into pRSETB (Invitrogen, Grand Island, NY, USA) to form pRSETB-sfiI-bG. The gene coding E. coli AIDA-I (pMK14 24 ), a kind gift from Dr Benz Inga (University of Mü nster, Mü nster, Germany), was digested with SmaI and ClaI, and then subcloned into pRSETB-sfiI-bG to create pRSETB-mbG-AIDA. The plasmid pTX101, 25 a kind gift from Dr George Georgiou (University of Texas, Austin, TX, America), was used as a template to amplify the coding sequence of lpp-membrane protein A with the following primers: 5 0 -CATATGATGAAAGCTACTAAT-GAAAGCTACTAAACTG-3 0 and 5 0 -GGCCCAGCCGGCCGTTGTCCGGACGAGT GCC-3 0 , and was subcloned into pRSETB to form pRSETB-lpp-bG.
Bacterial bG expression BL21 E. coli were transformed with pRSETB-bG-AIDA, pRSETB-lpp-bG or pRSETB-bG to form mbG/AIDA-BL21, lpp/mbG-BL21 and pbG-BL21 cells, respectively. bG expression was detected by western blotting, using a polyclonal rabbit anti-bG antibody. Transformed BL21 cells (OD 600 nm ¼ 0.1, 100 ml) were immediately mixed with 20 ml of reducing sample buffer and loaded onto an SDS-polyacrylamide gel electrophoresis (3% stacking gel; 8% running gel). Proteins were transferred onto nitrocellulose membranes (Hybond C-extra; Amersham, Piscataway, NJ, USA). Membranes were blocked in phosphate buffered saline-0.05% Tween, containing 5% nonfat milk for 1 h. Blocked membranes were then incubated with rabbit anti-E. coli bG antibody (G5420; Sigma-Aldrich, Schnelldorf, Germany) at a dilution of 1:2000 in phosphate buffered saline-0.05% Tween and 2.5% nonfat milk for 1 h. Membranes were washed and incubated with horseradishconjugated goat antirabbit IgG (1:2000) (Jackson ImmunoResearch, Soham, UK) in the same buffer for 1 h. After extensive washing in phosphate buffered saline-0.05% Tween, membranes were developed by an ECL luminescence kit (Millipore, Bedford, MA, USA) and exposed to X-ray film.
Surface-expressed bG on bacteria by enzyme-linked immunosorbent assay
Transformed bacteria mbG/AIDA-BL21, lpp/mbG-BL21 and pbG-BL21 were grown until OD 600 nm ¼ 0.35. Bacteria were collected and coated on a 96-well microtiter plate (1 Â 10 7 cfu per 50 ml per well) in 0.1 M NaHCO 3 (pH 7.8) at 4 1C overnight. After removing uncoated bacteria by extensive washing, the plates were blocked overnight with 2% nonfat milk at 4 1C and then incubated with 1 mg ml À 1 anti-hemagglutinin tag antibody (MMS-101P; Covance, Berkeley, CA, USA) in dilution buffer (PBS contains 2% nonfat milk) at room temperature for 1 h. The plates were washed with PBS and 50 ml ml À 1 horseradish-peroxidase-conjugated goat antimouse IgG Fc (0.5 mg ml À 1 ; Jackson ImmunoResearch) was added at room temperature for 1 h. The plates were washed as described above, and bound peroxidase was measured by adding 150 ml per well of 2,2'-azinobis (3-ethylbenzthiazoline-6-sulfonic acid) (Sigma) at 0.4 mg ml À 1 in the presence of 0.003% H 2 O 2 at room temperature for 30 min. Color development was measured at 405 nm by a microplate reader.
Analysis of bG activity bG activity was measured by monitoring the release of p-nitrophenol from PNPG (Sigma) Transformed BL21 cells (OD 600 nm ¼ 0.1, 50 ml) were washed five times with PBS, broken by ultrasonication and were immediately incubated with 100 ml of 0.625 mM PNPG in PBS containing 0.05% bovine serum albumin in a microtiter plate for 10 min. The absorbance at 405 nm was measured on a plate reader.
Cytotoxicity by pbG-BL21-or bG/AIDA-BL21-mediated conversion of prodrug HCT116 cells (5 Â 10 3 cells per well) grown overnight in 96-well microtiter plates were treated with graded concentrations of pHAM and HAMG provided by Dr Lu (Chia Nan University of Pharmacy and Science, Tainan, Taiwan), bG/AIDA-BL21 (2 Â 10 7 bacteria per well) þ HAMG or pbG-BL21 (2 Â 10 7 bacteria per well) þ HAMG at 37 1C for 15 min. The cells were washed three times with PBS and then cultured for an additional 72 h in fresh medium containing 25 mg ml À 1 gentamycin (Sigma), to kill residual bacteria. Cell viability was determined by the ATPlite luminescence ATP detection assay system (Perkin-Elmer Life and Analytical Science, Boston, MA, USA). Results are expressed as percent inhibition of luminescence as compared with untreated cells by the following formula:
% inhibition ¼ 100 Â (sample luminescence À background luminescence/ control luminescence À background luminescence).
RESULTS
Construction and expression of surface-expressed bG
To express bG on the bacterial surface, the gene coding E. coli bG was fused to the N terminus of the bacterial autotransporter AIDA-I gene or the C terminus of the bacterial lppompA gene to form the fusion proteins bG/AIDA and lpp/bG, respectively (Figure 2a) . In addition, a plasmid for expression of bG in the periplasmic space (pbG) was used as a control. 8 To confirm the expression of the different forms of bG, these plasmids were transformed into BL-21(DE3) bacteria to form mbG/AIDA-BL21, lpp/mbG-BL21 and pbG-BL21 cells, respectively. Western blotting with an anti-E. coli bG antibody showed that mbG/AIDA-BL21, lpp/mbG-BL21 and pbG-BL21 cells expressed bG/AIDA, lpp/bG and pbG, with the expected sizes of 125, 100 and 75 kDa, respectively (Figure 2b) . Surface display of a functional bG To investigate whether bG could be expressed on the surface of E. coli, mbG/AIDA-BL21 and lpp/mbG-BL21, cells were coated in 96-well microtiter plates, and the presence of bG on the cell surface was detected by enzyme-linked immunosorbent assay using an anti-hemagglutinin epitope tag antibody. The absorbance (representing bound antibody) in the wells coated with mbG/AIDA-BL21 (1.51±0.08) and mbG/lpp-BL21 (0.43±0.04) cells were significantly higher than in the wells coated with pbG-BL21 (0.06 ± 0.01) cells (Figure 3a) , indicating that AIDA-I and lpp-ompA could direct bG to the bacterial surface. To verify whether the recombinant bG fusion proteins on the bacterial surface retained enzymatic activity, BL21, mbG/AIDA-BL21, mbG/lpp-BL21 and pbG-BL21 cells were incubated with the bG substrate p-nitrophenyl b-D-glucuronide. Figure 3b shows that mbG/AIDA-BL21 cells (2.81±0.04) hydrolyzed more substrate than mbG/lpp-BL21 (0.04 ± 0.02) and pbG-BL21 (0.85 ± 0.01) cells, indicating that mbG/AIDA more effectively hydrolyzed substrate as compared with mbG/lpp or pbG. The enzymatic activities of mbG/AIDA-BL21, pbG-BL21 and pbG-BL21 were further compared by incubating bacteria or bacterial lysates with p-nitrophenyl-b-D-glucuronide and by measuring the absorbance at 405 nm at defined times. Figure 4 shows that generation of p-nitrophenol in mbG/AIDA-BL21 cells (slope ¼ 0.0237 ± 0.0002) was 2.6-fold faster than in pbG-BL21 cells (slope ¼ 0.009 ± 0.0002). By contrast, PNPG hydrolysis in pbG-BL21 lysates (slope ¼ 0.052 ± 0.001) was 5.7-fold faster than by intact pbG-BL21 cells, indicating that substrate hydrolysis in pbG-BL21 cells is limited by substrate entry into the cells, and expression of bG on the surface of bacteria can enhance the hydrolytic efficiency of glucronide substrate. mbG/AIDA-BL21-mediated cytotoxicity To examine whether mbG/AIDA-BL21 cells could efficiently convert a glucuronide anticancer prodrug to active drug, human colorectal cancer HCT116 cells were incubated with graded concentrations of pHAM, HAMG, mbG/AIDA-BL21 þ HAMG or pbG-BL21 þ HAMG for 15 min. The cells were then washed three times with PBS and were cultured for an additional 72 h in fresh medium. Cellular ATP synthesis was measured as an index of cell viability. Figure 5 shows that in the presence of mbG/AIDA-BL21 cells, the glucuronide prodrug HAMG (half maximal inhibitory concentration (IC 50 ): 226.53±45.4 mM) was nearly as toxic as active drug pHAM (IC 50 : 70.6±6.75 mM). By contrast, the IC 50 of HAMG (4500 mM) in the presence of pbG-BL2 cells was similar to HAMG alone (4500 mM). These results show that surface expression of bG on mbG/AIDA-BL21 cells facilitated more effective conversion of HAMG to pHAM, to kill HCT116 cancer cells.
DISCUSSION
We successfully expressed functional bG on the surface of bacteria by fusion to the autotransporter AIDA-I, to increase the conversion efficiency of glucuronide prodrugs. mbG/AIDA-BL21 cells rapidly and efficiently converted a hydrophilic glucuronide prodrug to an active anticancer drug to inhibit tumor cell growth. Thus, surface expression of bG increased the conversion efficiency of glucuronides, which may help to compensate low colonization efficiency of bacteria in some tumors. Many tumors evolve to evade control by the immune system through mechanisms, such as increased expression of FasL, 26, 27 decreased expression of vascular cell adhesion molecule-1 28 and hypoxia-induced adenosine accumulation. 29 Such mechanisms lead to impaired immune surveillance and provide a microenvironment supportive of bacterial survival and replication. Pawelek et al. 3 showed that Salmonella preferentially accumulate within tumors in mice, reaching ratios of bacteria in tumor and normal tissues as high as 1000:1. Bacteria can compete for nutrients, secret toxic products or activate prodrugs to cause cancer cell death. These observations have incited interest in developing bacteria-based tumor therapies. For example, Hoffman 30 developed a tumor-seeking S. typhimurium that demonstrated antitumor efficacy. Other experiments demonstrated that bacteria can transfer therapeutic genes [31] [32] [33] or produce therapeutic proteins 34, 35 to effectively inhibit tumor growth. Considering the ease of genetic manipulation in bacteria and that many bacteria can be cleared (or at least suppressed) by antibiotics when needed, BDEPT seems a promising treatment for cancer patients.
A wide variety of glucuronide prodrugs are available for cancer treatment, because they possess several potential advantages: (1) glucuronide prodrugs do not become activated systemically, because bG levels are very low in human serum; 36 (2) glucuronidation is an important detoxification metabolic process in mammals, 37, 38 reducing premature activation of glucuronide prodrugs by endogeneous bG in vivo; (3) glucuronide prodrugs are relatively nontoxic; 14 (4) glucuronide derivatives of most antineoplastic agents, such as doxorubicin, 39 etoposide, 40 paclitaxel 41 and alkylating agents, 16 can be synthesized by employing a linker between the drug and glucuronide moieties: 16, 42 therefore, a variety of potent glucuronide prodrugs are available for cancer treatment and (5) human bG displays optimal activity at pH 4.5, as it is mainly located in the lysosomes and microsomes of cells. By contrast, bacterial bG displays optimal activity at pH 7, consistent with its localization to the cytoplasm. 43 The pH in the interstitial tumor space is near 7, 44, 45 which is suitable for bacteria but not human bG-catalyzed hydrolysis of glucuronide prodrugs. Combining the advantages of glucuronide prodrugs with the tumor-targeting ability of some bacteria may be beneficial for clinical therapy of tumors.
Extracellular activation of glucuronide prodrugs by bG has been shown to increase therapeutic efficacy for cancer. Glucuronide derivatives do not permeate cells easily due to the presence of a charged carboxyl group. Accordingly, interaction of glucuronide prodrugs with lysosomal bG is minimal. 46 We previously showed that glucuronide prodrugs must be enyzmatically activated outside of tumor cells to achieve maximum cytotoxicity. 47 We also demonstrated that anchoring bG on the surface of tumor cells promoted effective activation of glucuronide prodrugs for enhanced cytotoxicity, which could overcome low transgenic efficiency in vivo. 16 In the present study, we expressed bG on the bacterial surface (mbG/AIDA-BL21) to enhance the conversion of a hydrophilic glucuronide prodrug. We observed that mbG/AIDA-BL21 cells could more rapidly and efficiently convert prodrug into active drugs as compared with pbG. Therefore, mbG/AIDA-BL21 cells may help overcome inadequate bacterial colonization in tumors and enhance the therapeutic efficacy of BDEPT.
Lpp-ompA-mediated surface expression has been demonstrated to allow expression of enzymes, 25, 48 single-chain antibodies 49 or antigenic pepitdes 50 on the bacterial surface. AIDA-I is a component of the bacterial b-autotransporter system, which has been used to express a variety of proteins on bacterial surfaces, including antigenic proteins, 51 ,52 enzymes 17 and dimeric adrenodoxin. 18 In our study, we constructed two kinds of mbG (mbG/AIDA and mbG/lpp) and examined their surface expression and function. Our results showed that both mbG/AIDA and mbG/lpp were expressed on the bacterial surface, but only mbG/AIDA-BL21 cells displayed bG activity. We speculate that the eight transmembrane domains of lpp-ompA may have prevented proper formation of bG tetramers, which is required for enzyme activity. 53 On the other hand, Jose et al. 18 demonstrated that the dimeric bovine adrenodoxin protein was readily expressed on the bacterial surface using AIDA-I, similar to our results with bG. Therefore, AIDA-I mediates more efficient expression of functional bG on bacterial surfaces than lpp-ompA.
In summary, we demonstrated that AIDA-I mediated efficient expression of functional bG on bacterial surfaces (mbG/AIDA-BL21). mbG/AIDA-BL21 cells more rapidly and efficiently converted the glucuronide substrate PNPG to p-nitrophenol than pbG (pbG/lpp-BL21), and it enhanced the cytoxicity of the glucuronide prodrug HAMG to active drug pHAM. These data suggest that surface expression of bG on bacteria can enhance prodrug conversion efficiency and help compensate inadequate colonization of bacteria to maximize the therapeutic efficacy of BDEPT. 
